ALLG MM23 : An ALLG phase 3 randomised trial of Selinexor and Lenalidomide-dexamethasone versus lenalidomide maintenance post Autologous stem cell transplant for patients with Newly Diagnosed multiple myeloma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

17+Age Over 17

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaMultiple Myeloma

Trial Overview Read MoreRead more

This phase III trial is comparing the use of an oral cancer drug (Lenalidomide) alone and in combination with chemotherapy (Selinexor) and a corticosteroid (Dexamethasone) in patients with newly diagnosed multiple myeloma who are currently undergoing Autologous stem cell transplant.
 

This trial is treating patients with multiple myeloma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had a certain type of treatment or surgical procedure.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

An ALLG phase 3 randomised trial of Selinexor and Lenalidomide-dexamethasone versus lenalidomide maintenance post Autologous stem cell transplant for patients with Newly Diagnosed multiple myeloma

Cooperative Group

Australasian Leukaemia and Lymphoma Group (ALLG)

Recruiting Hospitals Read MoreRead more

Austin Health
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Border Medical Oncology
Albury
Ms Nyree Sarakis
Nsarkis@bordermedonc.com.au
02 6064 1493

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

St Vincent's Hospital, Haematology Oncology Research
Fitzroy
Ms Lisa Demosthenous
lisa.demosthenous@svha.org.au
03 9231 3182

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next